Publications by authors named "G Pagani"
Aurora kinase A (AURKA) is a major regulator of the cell cycle. A prominent association exists between high expression of AURKA and cancer, and impairment of AURKA levels can trigger its oncogenic activity. In order to explore the contribution of post-transcriptional regulation to AURKA expression in different cancers, we carried out a meta-analysis of -omics data of 18 cancer types from The Cancer Genome Atlas (TCGA).
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the features and outcomes of fetal cardiac rhabdomyoma, comparing cases with and without prenatal treatment using mTOR inhibitors (mTORi).
- A review of 61 studies identified 400 fetuses, revealing various complications such as arrhythmias and effusions, with a notable 12% fetal demise rate; 60% of cases were also linked to tuberous sclerosis.
- The findings indicated that fetuses treated with mTORi showed improvements in tumor size and reduced complications, with no cases of fetal demise or neonatal death among the treated group.
Objectives: To report the diagnostic accuracy of cell-free DNA (cfDNA) in maternal blood in detecting chromosomal anomalies in twin pregnancies.
Methods: Medline, Embase and Cochrane databases were searched. The inclusion criteria were twin pregnancies undergoing cfDNA screening for Trisomies 13, 18, 21, monosomy X0 and other sex chromosomal anomalies (SCA).
The role of alternative polyadenylation of mRNA in sustaining aggressive features of tumors is quite well established, as it is responsible for the 3'UTR shortening of oncogenes and subsequent relief from miRNA-mediated repression observed in cancer cells. However, the information regarding the vulnerability of cancer cells to the inhibition of cleavage and polyadenylation (CPA) machinery is very scattered. Only few recent reports show the antitumor activity of pharmacological inhibitors of CPSF3, one among CPA factors.
View Article and Find Full Text PDFObjective: This study aimed to investigate the outcomes associated with the administration of maternal intravenous immunoglobulin in high-risk red blood cell-alloimmunized pregnancies.
Data Sources: Medline, Embase, and Cochrane Library were systematically searched until June 2023.
Study Eligibility Criteria: This review included studies reporting on pregnancies with severe red blood cell alloimmunization, defined as either a previous fetal or neonatal death or the need for intrauterine transfusion before 24 weeks of gestation in the previous pregnancy as a result of hemolytic disease of the fetus and newborn.